13 news items
Comparative Study: AbbVie And Industry Competitors In Biotechnology Industry
ABBV
11 Jun 24
and growth potential.
The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $4.49 Billion
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors
ABBV
JNJ
LLY
4 Jun 24
not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results
ABBV
JNJ
LLY
29 May 24
, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by InvestorBrandMedia.com or any third
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation
ABBV
JNJ
LLY
21 May 24
or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
ABBV
CRBP
CRDL
14 May 24
Impacts
The rescheduling is likely to alleviate financial pressures on cannabis businesses, notably by eliminating certain tax burdens
y8firvy1xnw7ri
ABBV
ATNM
AZN
8 May 24
or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content
4uqgkwiklx8yoegymzcsw 0ixeh4qoj
ABBV
ATNM
AZN
22 Apr 24
informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer
jnonfbocfq65 vmxk1olowytyki9a3pd3ys
ABBV
ATNM
AZN
19 Apr 24
a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article
7hh6kkqtsx0lw7m88l3us3wkw8q8b
ABBV
12 Apr 24
for the first quarter of 2024 "are expected to include acquired IPR&D and milestones expense of $164 million on a pre-tax basis, representing
1ckw5
ABBV
12 Apr 24
quarter of 2024 "are expected to include acquired IPR&D and milestones expense of $164 million on a pre-tax basis, representing an unfavorable impact
8jcmh1y1ket i1tw
ABBV
10 Apr 24
that its earnings for the first quarter of 2024 "are expected to include acquired IPR&D and milestones expense of $164 million on a pre-tax basis
xvfn1kzp70ftp638a6bcis14tpikmttnfjvxeqbdql 0l
ABBV
26 Mar 24
to various factors.
The company has higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $3.85
n1mk3krg7j6fhuevqi7xa7gp8yts7iq6mnbi
ABBV
ANIX
BIIB
20 Mar 24
a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice
- Prev
- 1
- Next